SCHEMBL141399

SCHEMBL141399

COc1ccc2nc(Nc3cc(Cc4ccccc4)nc(Nc4ccc(O)cc4)n3)sc2c1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB Q96GD4 9/20 0.68
LCK P06239 8/20 0.68
ITK Q08881 8/20 0.68
MEN1 O00255 8/20 0.57
KMT2A Q03164 8/20 0.57
MAPT P10636 7/20 0.57
NPC1 O15118 6/20 0.57
RAB9A P51151 6/20 0.57
SMN1; SMN2 Q16637 6/20 0.57
NFKB1 P19838 4/20 0.57
NFKB2 Q00653 4/20 0.57
RELA Q04206 4/20 0.57
EGFR P00533 1/20 0.52
INSR P06213 1/20 0.52
SRC P12931 1/20 0.52
TEC P42680 1/20 0.52
TXK P42681 1/20 0.52
BMX P51813 1/20 0.52
BTK Q06187 1/20 0.52
LRRK2 Q5S007 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257970 0.91 AURKB (0.66) AURKBLCKITKMEN1KMT2A
SCHEMBL141009 0.91 AURKB (0.65) AURKBLCKITKMEN1KMT2A
SCHEMBL141497 0.90 AURKB (0.64) AURKBLCKITKMEN1KMT2A
SCHEMBL141477 0.88 AURKB (0.63) AURKBLCKITKMEN1KMT2A
SCHEMBL262100 0.87 AURKB (0.60) AURKBLCKITKMEN1KMT2A
SCHEMBL140042 0.84 AURKB (0.68) AURKBLCKITKMEN1KMT2A
SCHEMBL178941 0.81 AURKB (0.69) AURKBLCKITKMEN1KMT2A
SCHEMBL144939 0.81 ITK (1.00) AURKBLCKITKMEN1KMT2A
SCHEMBL144940 0.81 ITK (1.00) AURKBLCKITKMEN1KMT2A
SCHEMBL141866 0.81 LCK (0.63) AURKBLCKITKMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK AURKB 53/4885LCK 189/4885ITK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.